These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26871947)

  • 21. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
    Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
    Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
    Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
    Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
    Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.
    Muniyan S; Chou YW; Ingersoll MA; Devine A; Morris M; Odero-Marah VA; Khan SA; Chaney WG; Bu XR; Lin MF
    Cancer Lett; 2014 Oct; 353(1):59-67. PubMed ID: 25050738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
    Batra A; Winquist E
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
    Ming DS; Pham S; Deb S; Chin MY; Kharmate G; Adomat H; Beheshti EH; Locke J; Guns ET
    J Steroid Biochem Mol Biol; 2014 Sep; 143():19-28. PubMed ID: 24565566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
    Gordon JA; Midha A; Szeitz A; Ghaffari M; Adomat HH; Guo Y; Klassen TL; Guns ES; Wasan KM; Cox ME
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):21-7. PubMed ID: 26238234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
    Xue X; Zhang Y; Wang C; Zhang M; Xiang Q; Wang J; Wang A; Li C; Zhang C; Zou L; Wang R; Wu S; Lu Y; Chen H; Ding K; Li G; Xu Y
    Eur J Med Chem; 2018 May; 152():542-559. PubMed ID: 29758518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
    Saeed K; Rahkama V; Eldfors S; Bychkov D; Mpindi JP; Yadav B; Paavolainen L; Aittokallio T; Heckman C; Wennerberg K; Peehl DM; Horvath P; Mirtti T; Rannikko A; Kallioniemi O; Östling P; Af Hällström TM
    Eur Urol; 2017 Mar; 71(3):319-327. PubMed ID: 27160946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
    Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.
    Zhu YP; Wan FN; Shen YJ; Wang HK; Zhang GM; Ye DW
    Oncotarget; 2015 Jun; 6(16):14488-96. PubMed ID: 25895032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
    Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
    Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
    Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
    Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.